Delivery Order SPE2DB22D2214-SPE2DB25FS6LC
- Not listed
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,077.55 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside arrangement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,785.59 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order represents part of AmerisourceBergen's broader pharmaceutical supply operations supporting federal medical procurement needs. The company, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,205.08 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,840.04 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens. This firm fixed-price delivery order, with an ultimate completion date of September 12, 2025, represents a competitively awarded contract with no set-aside designation. The product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $32,717.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The contract was fulfilled from the...
- The Defense Logistics Agency awarded a $31,248.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections on August 20, 2025, with completion targeted for August 21, 2025. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $6,125.92 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on September 15, 2025, with completion targeted for September 16, 2025. This non-competitive delivery order utilizes a firm fixed price structure and represents a small-value pharmaceutical supply transaction. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6LCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $34,983.20 on September 4, 2025, for Zepbound (semaglutide) 5 mg/0.5 mL pens with a completion date of September 5, 2025. This is a firm fixed-price, non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's prime IDC with DLA provides a comprehensive vehicle for supplying pharmaceuticals and medical commodities globally across multiple therapeutic domains. This delivery order reflects routine procurement activities under that broader contract, supplying specialty medications to support Defense Health Agency operations and other government healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.0k | 9/4/25 |